Loading clinical trials...
Loading clinical trials...
EXtended Therapy in Genotype 3 Infected Patients Who do Not AChieve a Treatment Response at Week 4 (RVR) But do Achieve a Complete Early Virologic Response (cEVR)
Conditions
Interventions
Peginterferon alfa-2b (Pegetron) plus ribavirin (Rebetol)
Locations
12
Canada
Calgary Heart Centre
Calgary, Alberta, Canada
Hys Med Centre
Edmonton, Alberta, Canada
Liver and Intestinal Research Centre
Vancouver, British Columbia, Canada
Dr. John D Farley Medical Office
Vancouver, British Columbia, Canada
Pacific Gastroenterology Assoc
Vancouver, British Columbia, Canada
Hotel Dieu Hospital
Kingston, Ontario, Canada
Start Date
February 1, 2010
Primary Completion Date
June 1, 2011
Completion Date
June 1, 2011
Last Updated
September 29, 2011
NCT00199719
NCT06922643
NCT03612973
NCT01866930
NCT05895448
NCT02219490
Lead Sponsor
University Health Network, Toronto
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions